A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor
positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic
breast cancer. The main goals of this study are to:
- Find the recommended dose of AC682 that can be given safely to participants
- Learn more about the side effects of AC682
- Learn more about pharmacokinetics of AC682
- Learn more about the effectiveness of AC682